The Greater Cannabis Company, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 17, 2021 at 06:07 am EDT
Share
The Greater Cannabis Company, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 86,232 compared to USD 88,097 a year ago. Net loss was USD 114,653 compared to USD 1.211 million a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.03 a year ago.
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.